Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients
Abstract
Cognitive decline is inadequately captured by the standard neurological examination. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are biomarkers of neuronal damage and astrocytic reactivity that may offer an accessible measure of the multiple sclerosis (MS) pathology linked to cognitive decline.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 30, 2022
- Source ID
- 10.1177/13524585221137697
Entities
People
- Anu Paul
- Bonnie I Glanz
- Brian C. Healy
- Charles Rg Guttmann
- Christian Barro
- Howard L. Weiner
- Mariann Polgar-Turcsanyi
- Rohit Bakshi
- Shrishti Saxena
- Tanuja Chitnis
Organizations
- Chiron Corporation
- Harvard Medical School
- Swiss National Science Foundation
- United States Department of Defense